TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID OTC
Generic Name and Formulations:
Acetaminophen 325mg, doxylamine succinate 6.25mg, dextromethorphan HBr 10mg, phenylephrine HCl 5mg; per 15mL; Citrus Burst liq; contains sodium 5mg/15mL.
McNeil Consumer Healthcare
Indications for TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID:
Congestion, rhinorrhea, cough, sore throat, headache, fever, minor aches and pains.
30mL every 4 hours; max 180mL/24 hours.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Glaucoma. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
Analgesic + antihistamine + antitussive + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline